{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T18:45:40Z","timestamp":1791398740144,"version":"4.3.3"},"reference-count":32,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2015,12,7]],"date-time":"2015-12-07T00:00:00Z","timestamp":1449446400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0144337","type":"journal-article","created":{"date-parts":[[2015,12,8]],"date-time":"2015-12-08T16:52:31Z","timestamp":1449593551000},"page":"e0144337","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":161,"title":["Adverse Effects of Cholinesterase Inhibitors in Dementia, According to the Pharmacovigilance Databases of the United-States and Canada"],"prefix":"10.1371","volume":"10","author":[{"given":"Thibault B.","family":"Ali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas R.","family":"Schleret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian M.","family":"Reilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winston Yuchen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben","family":"Abagyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2015,12,7]]},"reference":[{"key":"ref1","unstructured":"Administration USF and D. FDA Adverse Event Reporting System (FAERS) [Internet]. 2014. Available: http:\/\/www.fda.gov\/Drugs\/GuidanceComplianceRegulatoryInformation\/Surveillance\/AdverseDrugEffects\/<\/ext-link>"},{"key":"ref2","unstructured":"Health Canada. Canada Vigilance Adverse Reaction Online Database [Internet]. 2014. Available: http:\/\/www.hc-sc.gc.ca\/dhp-mps\/medeff\/databasdon\/index-eng.php<\/ext-link>"},{"key":"ref3","unstructured":"Medicine USNL of. Dementia: MedlinePlus [Internet]. Available: https:\/\/www.nlm.nih.gov\/medlineplus\/dementia.html<\/ext-link>"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"111","DOI":"10.31887\/DCNS.2009.11.2\/cqiu","article-title":"Epidemiology of Alzheimer\u2019s disease: Occurrence, determinants, and strategies toward intervention","author":"C Qiu","year":"2009","journal-title":"Dialogues in Clinical Neuroscience"},{"key":"ref5","unstructured":"World Health Organisation. the Epidemiology and Impact of Dementia Current State of Dementia: Current State and [Internet]. 2015 pp. 1\u20134. Available: http:\/\/www.who.int\/mental_health\/neurology\/dementia\/dementia_thematicbrief_epidemiology.pdf<\/ext-link>"},{"key":"ref6","unstructured":"Guerchet M, Prina M, Prince M. Policy Brief for Heads of Government: The Global Impact of Dementia 2013\u20132050 [Internet]. 2013. Available: https:\/\/www.alz.co.uk\/research\/GlobalImpactDementia2013.pdf<\/ext-link>"},{"key":"ref7","unstructured":"Prince M, Prina M, Guerchet M. World Alzheimer Report 2013 Journey of Caring: An Analysis of Long-Term Care for Dementia [Internet]. 2013. Available: http:\/\/www.alz.co.uk\/research\/world-report-2013<\/ext-link>"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jalz.2012.11.007","article-title":"The global prevalence of dementia: a systematic review and metaanalysis","volume":"9","author":"M Prince","year":"2013","journal-title":"Alzheimers Dement"},{"key":"ref9","first-page":"137","article-title":"Epidemiology of Alzheimer disease","volume":"7","author":"C Reitz","year":"2012","journal-title":"Epidemiology of Alzheimer disease"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1136\/bmj.318.7184.633","article-title":"Efficacy and safety of rivastigmine in patients with Alzheimer\u2019s disease: international randomised controlled trial","volume":"318","author":"M R\u00f6sler","year":"1999","journal-title":"BMJ"},{"key":"ref11","article-title":"IDEAL: A 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease","author":"B Winblad","year":"2007","journal-title":"Neurology"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3988\/jcn.2011.7.3.137","article-title":"Efficacy and safety of switching from oral cholinesterase inhibitors to the rivastigmine transdermal patch in patients with probable Alzheimer\u2019s disease","volume":"7","author":"HJ Han","year":"2011","journal-title":"J Clin Neurol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1034\/j.1600-0536.2002.470302.x","article-title":"Tetrazepam drug sensitivity\u2014usefulness of the patch test","author":"C Pirker","year":"2002","journal-title":"Contact dermatitis"},{"key":"ref14","unstructured":"Gruber T, Jody D. Novartis Pharmaceutical Important Drug Warning Exelon. In: U.S. Food and Drug Administration [Internet]. 2007. Available: http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/EnforcementActivitiesbyFDA\/WarningLettersandNoticeofViolationLetterstoPharmaceuticalCompanies\/ucm054180.pdf<\/ext-link>"},{"key":"ref15","unstructured":"Winston C, Abagyan R. Early Drug Alert [Internet]. 2014. Available: http:\/\/earlydrugalert.ucsd.edu\/<\/ext-link>"},{"key":"ref16","unstructured":"Chen M. Overview of Postmarketing Safety Reporting and Pharmacovigilance in CDER [Internet]. 2013. Available: http:\/\/www.fda.gov\/downloads\/Drugs\/DevelopmentApprovalProcess\/SmallBusinessAssistance\/UCM377660.pdf<\/ext-link>"},{"key":"ref17","unstructured":"U.S. Food and Drug Administration. FDA Adverse Event Reporting System Latest Quarterly Data Files [Internet]. 2014. Available: http:\/\/www.fda.gov\/Drugs\/GuidanceComplianceRegulatoryInformation\/Surveillance\/AdverseDrugEffects\/ucm082193.htm<\/ext-link>"},{"key":"ref18","unstructured":"Health Canada. Search the Canada Vigilance Adverse Reaction Online Database [Internet]. 2014. Available: http:\/\/webprod3.hc-sc.gc.ca\/arquery-rechercheei\/index-eng.jsp<\/ext-link>"},{"key":"ref19","unstructured":"Health Canada. Instructions for the Canada Vigilance Adverse Reaction Online Database [Internet]. 2013. Available: http:\/\/www.hc-sc.gc.ca\/dhp-mps\/medeff\/databasdon\/instructions-eng.php<\/ext-link>"},{"key":"ref20","first-page":"227","article-title":"Explaining Odds Ratios","author":"M Szumilas","year":"2010","journal-title":"J Can Acad Child Adolesc Psychiatry"},{"key":"ref21","unstructured":"MedCalc\u00ae<\/sup>. User-friendly statistical software. In: 2015 [Internet]. Available: https:\/\/www.medcalc.org\/index.php<\/ext-link>"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA adverse event reporting system","volume":"10","author":"T Sakaeda","year":"2013","journal-title":"Int J Med Sci"},{"key":"ref23","first-page":"359","article-title":"Comparison of Sensitivity and Timing of Early Signal Detection of Four Frequently Used Signal Detection Methods","volume":"22","author":"Y Chen","year":"2008","journal-title":"Pharmaceut Med"},{"key":"ref24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0042866","article-title":"A survey of the FDA\u2019s AERS database regarding muscle and tendon adverse events linked to the statin drug class","volume":"7","author":"KB Hoffman","year":"2012","journal-title":"PLoS One"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1755-5949.2010.00141.x","article-title":"Drug profile: Transdermal rivastigmine patch in the treatment of alzheimer disease","author":"M Emre","year":"2010","journal-title":"CNS Neuroscience and Therapeutics"},{"key":"ref26","article-title":"A Fatal Outcome After Unintentional Overdosing of Rivastigmine Patches","author":"H Lovborg","year":"2012","journal-title":"Current Drug Safety"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2165\/00002512-200421070-00004","article-title":"Cholinesterase inhibitors used in the treatment of Alzheimer\u2019s disease: the relationship between pharmacological effects and clinical efficacy","volume":"21","author":"DG Wilkinson","year":"2004","journal-title":"Drugs Aging"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1517\/14656566.1.1.121","article-title":"The pharmacology of donepezil: a new treatment of Alzheimer\u2019s disease","volume":"1","author":"DG Wilkinson","year":"1999","journal-title":"Expert Opin Pharmacother"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2174\/157488410791110805","article-title":"A review of clinical pharmacokinetics and pharmacodynamics of galantamine, a reversible acetylcholinesterase inhibitor for the treatment of Alzheimer\u2019s disease, in healthy subjects and patients","volume":"5","author":"F Huang","year":"2010","journal-title":"Curr Clin Pharmacol"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1592\/phco.20.1.1.34664","article-title":"Rivastigmine, a new-generation cholinesterase inhibitor for the treatment of Alzheimer\u2019s disease","volume":"20","author":"MW Jann","year":"2000","journal-title":"Pharmacotherapy"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1021\/bi020016x","article-title":"Kinetic and Structural Studies on the Interaction of Cholinesterases with the","volume":"41","author":"P Bar-On","year":"2002","journal-title":"Biochemistry"},{"key":"ref32","first-page":"14","article-title":"Case Report A Rare Case of Acute Renal Failure Secondary to Rhabdomyolysis Probably Induced by Donepezil","volume":"2014","author":"OZ Sahin","year":"2014","journal-title":"Case Report A Rare Case of Acute Renal Failure Secondary to Rhabdomyolysis Probably Induced by Donepezil"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0144337","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,28]],"date-time":"2022-05-28T11:13:11Z","timestamp":1653736391000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0144337"}},"subtitle":[],"editor":[{"given":"Andrea","family":"Cavalli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2015,12,7]]},"references-count":32,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2015,12,7]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0144337","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,7]]}}}